- Home
- CARM vs LYRA Comparison
CARM vs LYRA Comparison
Compare CARM & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CARM
- LYRA
- Stock Information
- Founded
- CARM 2016
- LYRA 2005
- Country
- CARM United States
- LYRA United States
- Employees
- CARM N/A
- LYRA N/A
- Industry
- CARM Biotechnology: Pharmaceutical Preparations
- LYRA Medical/Dental Instruments
- Sector
- CARM Health Care
- LYRA Health Care
- Exchange
- CARM Nasdaq
- LYRA Nasdaq
- Market Cap
- CARM 12.2M
- LYRA 11.6M
- IPO Year
- CARM N/A
- LYRA 2020
- Fundamental
- Price
- CARM $0.24
- LYRA $7.47
- Analyst Decision
- CARM Hold
- LYRA Hold
- Analyst Count
- CARM 5
- LYRA 1
- Target Price
- CARM $0.90
- LYRA $16.00
- AVG Volume (30 Days)
- CARM 447.9K
- LYRA 21.6K
- Earning Date
- CARM 08-07-2025
- LYRA 08-12-2025
- Dividend Yield
- CARM N/A
- LYRA N/A
- EPS Growth
- CARM N/A
- LYRA N/A
- EPS
- CARM N/A
- LYRA N/A
- Revenue
- CARM $10,767,000.00
- LYRA $770,000.00
- Revenue This Year
- CARM N/A
- LYRA N/A
- Revenue Next Year
- CARM N/A
- LYRA $139.18
- P/E Ratio
- CARM N/A
- LYRA N/A
- Revenue Growth
- CARM N/A
- LYRA N/A
- 52 Week Low
- CARM $0.14
- LYRA $3.81
- 52 Week High
- CARM $1.27
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- CARM 31.94
- LYRA 48.46
- Support Level
- CARM $0.21
- LYRA $6.92
- Resistance Level
- CARM $0.31
- LYRA $7.57
- Average True Range (ATR)
- CARM 0.03
- LYRA 0.46
- MACD
- CARM -0.00
- LYRA 0.18
- Stochastic Oscillator
- CARM 23.64
- LYRA 90.57
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.